跳到主要內容區塊

水產疫苗評估、發展與應用技術建立之研究-海鱺發光菌與弧菌口服疫苗

  • 日期:98-04-21
  • 年度:2008
  • 領域:生物技術領域
  • 主持人:張正芳
  • 研究人員:張正芳

二株病原弧菌Vibrio fluvialis與V. alginolyticus,其病原性強,箱網養殖海鱺魚體虛弱時會發生爆發性死亡,本計劃針對此二株弧菌之注射疫苗之持續效力試驗及研製成口服顆粒狀態,添加於海鱺飼料中以增強對病原弧菌之抵抗力。試驗結果顯示,弧菌注射疫苗處理3週後,進行連續式攻毒試驗,疫苗之保護效力(RPS)可維持30週以上。而經分段式攻毒試驗,疫苗之保護效力也可維持12週。弧菌口服疫苗對於海鱺之安全劑量為0.1-1.6 mg/fish,而實驗室攻毒結果,口服弧菌疫苗3週後,V. fluvialis疫苗組之RPS最高為62.2其次為V. alginolyticus組為38.9,二者混合組則最低為13.0。

研究報告摘要(英)


The Vibrio fluvialis and V. alginolyticus have been attributed to a measurable mass mortality in the course of the sea cage culture of the cobia, Rachycentron canadium. This study aims to detect the relative percentage survival (RPS) effect of the vibrio injected vaccine and develop the vibrio oral vaccine to enhance protection of cobia against vibrio infection. The results showed that the RPS of the vibrio injected vaccine on cobia challenged with injection of V. alginolyticus and V. fluvialis were lasted to 12 weeks and lasted over 30 weeks in the separate and continued challenge test after the fish by vaccine treatments for 3 weeks, respectively. In the safety test of the vibrio oral vaccine was 0.1 to 1.6 mg/fish to the cobia after vaccination. The RPS of the vibrio oral vaccine in the V. fluvialis vaccine was 62.2, in the V. alginolyticus was 38.9 and in the both mixed was 13.0 after the fish by vaccine treatments for 3 weeks.